SOURCE: annual_report_text (1).txt
CHUNK: 78 of 1106
SIZE: 620 characters
PREVIOUS: chunk_0077_annual_report_text (1).txt
NEXT: chunk_0079_annual_report_text (1).txt
------------------------------
=== Page 23 ===
PanTeras use of actinium-225 is part of its broader mission 
to bring innovative and effective cancer treatments 
to patients around the world. By leveraging the expertise 
of IBA and SCK CEN in radiopharmaceutical development 
and nuclear medicine, the joint-venture is well positioned 
to develop innovative therapies that can enhance 
cancer patients quality of life. PANTERA
A BETTER FIGHT FOR LIFE
PanTera is a joint-venture created by IBA and the Belgian 
Nuclear Research Centre SCK CEN, focusing on the development 
and commercialization of radiopharmaceuticals for cancer 
diagnosis and therapy.